RAD51 Paralogs: Roles in DNA Repair & Cancer Risk

Recent advances in cryo-electron microscopy are shedding new light on the intricate mechanisms of DNA repair, specifically how cells mend double-strand breaks – a critical process for maintaining genomic stability and preventing cancer. A new study, published in Science, details the visualization of RAD51 filament assembly and its regulation by a complex involving XRCC3, RAD51C, RAD51D, and XRCC2. This research offers a deeper understanding of homologous recombination, a key pathway for repairing damaged DNA, and could inform future strategies for treating cancers linked to defects in these genes.

Homologous Recombination: The Cell’s DNA Repair Crew

Our DNA is constantly under assault from both internal and external factors, leading to breaks in the double helix. While cells have several repair mechanisms, homologous recombination (HR) is particularly important for accurately fixing these breaks, especially those that occur during DNA replication. HR uses an undamaged DNA template – often the sister chromatid – to guide the repair process, ensuring high fidelity. The RAD51 protein is central to this process, forming a filament on the damaged DNA strand and searching for the matching sequence on the template.

However, RAD51 doesn’t work alone. It collaborates with a family of related proteins, known as RAD51 paralogs. These paralogs – RAD51B, RAD51C, RAD51D, and XRCC2 – play crucial roles in regulating RAD51 activity and ensuring the repair process happens efficiently, and accurately. Mutations in these genes are increasingly recognized as contributing to an elevated risk of cancers, particularly breast and ovarian cancer. Understanding how these proteins interact is therefore vital.

Visualizing the Repair Machinery in Action

The study utilized cryo-electron microscopy (cryo-EM), a powerful technique that allows scientists to visualize biological molecules at near-atomic resolution. By freezing samples rapidly and imaging them with an electron microscope, researchers can capture snapshots of proteins in their native state, without the need for crystallization. This is particularly important for studying large, dynamic complexes like the RAD51 filament. Researchers were able to visualize how the XRCC3-RAD51C-RAD51D-XRCC2 complex interacts with and regulates the RAD51 filament, effectively “end-capping” it and controlling its activity.

Specifically, the research identified a mutation cluster within the Walker B region of RAD51C that affects its ability to interact with other RAD51 paralogs. This finding is significant because it helps explain the functional consequences of many variants of unknown significance (VUS) found in cancer patients. The study also revealed that RAD51C can uncouple its enzymatic activities related to homologous recombination and DNA replication, suggesting a more nuanced role for this protein than previously understood.

The Role of RAD51C/D and Homologous Recombination Deficiency

Germline mutations in RAD51C and RAD51D are associated with an increased risk of ovarian and breast cancer. A retrospective cohort study published in PubMed examined 181 patients carrying these mutations and found that 86.7% were women, and 55.8% had received a cancer diagnosis, primarily breast or ovarian cancer. The study also assessed the prevalence of homologous recombination deficiency (HRD) in tumor samples, finding functional HRD in 55.2% of breast and ovarian cancers tested. HRD refers to the inability of a cell to efficiently repair DNA breaks via homologous recombination, making it more susceptible to the effects of certain cancer therapies, such as platinum-based chemotherapy.

The identification of specific prevalent mutations, such as c.1026+5_1026+7del and c.709C>T in RAD51C, and c.694C>T in RAD51D, provides valuable information for genetic testing and risk assessment. Understanding the HRD status of tumors in patients with these germline mutations is crucial for guiding treatment decisions and potentially improving survival rates.

Implications for Cancer Treatment and Genetic Counseling

The findings from these studies have important implications for cancer treatment. Tumors with HRD are often more sensitive to platinum-based chemotherapies and PARP inhibitors, drugs that exploit the cell’s inability to repair DNA damage. Identifying patients with HRD, through genetic testing or functional assays like the RAD51 test described in Annals of Oncology, can help clinicians select the most effective treatment strategies.

this research underscores the importance of genetic counseling for individuals with a family history of breast or ovarian cancer. Identifying germline mutations in RAD51C or RAD51D can inform decisions about preventative measures, such as increased surveillance or prophylactic surgery. The ability to classify variants of unknown significance (VUS) in RAD51C, as highlighted in the Nature study, is particularly valuable for providing accurate risk assessments to patients and their families.

What Comes Next: Refining HRD Biomarkers and Therapeutic Strategies

The field of HRD biomarker research is rapidly evolving. Ongoing efforts are focused on developing more comprehensive and reliable tests to identify patients with HRD. This includes refining genomic instability scores, improving functional assays, and integrating multiple biomarkers to provide a more accurate assessment of repair pathway status. Clinical trials are also underway to evaluate the efficacy of PARP inhibitors and other targeted therapies in patients with HRD, aiming to personalize cancer treatment based on the specific genetic and functional characteristics of their tumors. Further research will also focus on understanding the precise mechanisms by which RAD51 paralogs regulate HR, potentially revealing new therapeutic targets for restoring DNA repair function in cancer cells.